Paid Clinical Trials Fargo
Discover 175 paid clinical trials in Fargo, North Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12
Sponsor:
Essentia Health
Location:
Code:
NCT05454189
Conditions
Maintenance of Implanted Port Devices
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Reduced IPD Flush Schedule
Standard IPD Flush Schedule
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib CreamA Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
Sponsor:
Incyte Corporation
Location:
Code:
NCT06213831
Conditions
Prurigo Nodularis
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
Ruxolitinib Cream 1.5%
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible UrticariaA Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria
Sponsor:
Evommune, Inc.
Location:
Code:
NCT06603220
Conditions
Chronic Inducible Urticaria
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
Oral EVO756
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesA Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Sponsor:
Novo Nordisk A/S
Location:
Code:
NCT06542874
Conditions
Type 2 Diabetes (T2D)
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
NNC0487-0111 subcutanous
Placebo (NNC0487-0111 subcutanous)
NNC0487-0111 oral
Placebo (NNC0487-0111 oral)
SPYRAL AFFIRM Global Study of RDN with the Symplicity Spyral RDN System in Subjects with Uncontrolled HTNSPYRAL AFFIRM Global Study of RDN with the Symplicity Spyral RDN System in Subjects with Uncontrolled HTN
Sponsor:
Medtronic Vascular
Location:
Code:
NCT05198674
Conditions
Hypertension
Vascular Diseases
Cardiovascular Diseases
Chronic Kidney Diseases
Diabetes Mellitus
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Renal Denervation (Symplicity Spyralâ„¢)
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous PolypsFive or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Sponsor:
NRG Oncology
Location:
Code:
NCT05080673
Conditions
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Eligibility Criteria
Sex: All
Age: 50 - 70
Healthy Volunteers: Not accepted
Interventions
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT03486873
Conditions
Solid Tumors
Hematologic Malignancies
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Standard of Care (SOC)
Lenvatinib
Olaparib
MK-4280
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03866382
Conditions
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE TrialDeveloping an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT06216574
Conditions
Breast Cancer Female
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Internet-based Intervention